These coordinated interactions drive mitochondrial transfer, tumor aggressiveness, and therapy resistance, consistent with clinical data showing that high HMGB1, RHOT1, or RAC1 expression correlates with shorter overall survival in HCC patients [63]. This evidence concerns the gene RHOT1 and neoplasm.